According to Regeneron Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 26.3555. At the end of 2022 the company had a P/E ratio of 17.8.
Year | P/E ratio | Change |
---|---|---|
2022 | 17.8 | 115.55% |
2021 | 8.26 | -43.98% |
2020 | 14.7 | -23.92% |
2019 | 19.4 | 17.5% |
2018 | 16.5 | -50.5% |
2017 | 33.3 | -22.28% |
2016 | 42.9 | -51.34% |
2015 | 88.1 | -23.31% |
2014 | 115 | 80.78% |
2013 | 63.6 | 192.43% |
2012 | 21.7 | -195.69% |
2011 | -22.7 | -12.12% |
2010 | -25.9 | -9.13% |
2009 | -28.4 | 56.49% |
2008 | -18.2 | 20.44% |
2007 | -15.1 | 33.11% |
2006 | -11.3 | 21.23% |
2005 | -9.35 | -177.18% |
2004 | 12.1 | -276.3% |
2003 | -6.87 | 5.09% |
2002 | -6.54 | -57.96% |
2001 | -15.6 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 10.7 | -59.22% | ๐บ๐ธ USA |
Novartis NVS | 27.6 | 4.81% | ๐จ๐ญ Switzerland |
Amgen AMGN | 22.0 | -16.50% | ๐บ๐ธ USA |
Sanofi SNY | 15.6 | -40.94% | ๐ซ๐ท France |
Biogen BIIB | 12.3 | -53.37% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | -36.0 | -236.53% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.